Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Clinical Efficacy of Hyaluronic Acid with Iodine in Hard-to-Heal Wounds

J. Pecová, V. Rohlíková, M. Šmoldasová, J. Marek

. 2023 ; 15 (9) : . [pub] 20230901

Status not-indexed Language English Country Switzerland

Document type Journal Article

Grant support
NA Contipro (Czechia)

Hard-to-heal wounds do not heal spontaneously and need long-term care provided by specialists. That burdens the patients as well as the healthcare systems. Such wounds arise from several pathologies, which result in venous leg ulcers (VLU), diabetic foot ulcers (DFU), pressure ulcers (PU), or ulcers originating from post-surgical wounds (pSW). Given the complex nature of hard-to-heal wounds, novel treatments are sought to enable wound healing. We tested the clinical efficacy and applicability of fluid comprising hyaluronic acid and iodine complex (HA-I) in the treatment of hard-to-heal wounds. Patients (n = 56) with VLU, DFU, PU, or pSW hospitalised in multiple wound-care centres in the Czech Republic were treated with HA-I. Wound size, classically visible signs of infection, exudation, pain, and wound bed appearance were monitored for 12 weeks. The highest healing rate was in DFU (71.4%), followed by pSW (62.5%), VLU (55.6%), and PU (44.4%). Classical visible signs of infection were resolved within 8 weeks in all types of wounds. Wound bed appearance improved most noticeably in pSW and then in VLU. Exudation was lowered most significantly in DFU and pSW. The highest decrease in pain was in pSW and DFU. The treatment with HA-I successfully led to either complete closure or significant improvement in the wound's healing. Therefore, the complex of hyaluronic acid and iodine is suitable for the treatment of hard-to-heal wounds of various aetiologies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015323
003      
CZ-PrNML
005      
20231020093525.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics15092268 $2 doi
035    __
$a (PubMed)37765236
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pecová, Jana $u Medical Faculty, Masaryk University in Brno, 62500 Brno, Czech Republic
245    10
$a Clinical Efficacy of Hyaluronic Acid with Iodine in Hard-to-Heal Wounds / $c J. Pecová, V. Rohlíková, M. Šmoldasová, J. Marek
520    9_
$a Hard-to-heal wounds do not heal spontaneously and need long-term care provided by specialists. That burdens the patients as well as the healthcare systems. Such wounds arise from several pathologies, which result in venous leg ulcers (VLU), diabetic foot ulcers (DFU), pressure ulcers (PU), or ulcers originating from post-surgical wounds (pSW). Given the complex nature of hard-to-heal wounds, novel treatments are sought to enable wound healing. We tested the clinical efficacy and applicability of fluid comprising hyaluronic acid and iodine complex (HA-I) in the treatment of hard-to-heal wounds. Patients (n = 56) with VLU, DFU, PU, or pSW hospitalised in multiple wound-care centres in the Czech Republic were treated with HA-I. Wound size, classically visible signs of infection, exudation, pain, and wound bed appearance were monitored for 12 weeks. The highest healing rate was in DFU (71.4%), followed by pSW (62.5%), VLU (55.6%), and PU (44.4%). Classical visible signs of infection were resolved within 8 weeks in all types of wounds. Wound bed appearance improved most noticeably in pSW and then in VLU. Exudation was lowered most significantly in DFU and pSW. The highest decrease in pain was in pSW and DFU. The treatment with HA-I successfully led to either complete closure or significant improvement in the wound's healing. Therefore, the complex of hyaluronic acid and iodine is suitable for the treatment of hard-to-heal wounds of various aetiologies.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rohlíková, Vladimíra $u Vsetín Hospital, 75501 Vsetín, Czech Republic
700    1_
$a Šmoldasová, Markéta $u Hospital in Ústí nad Orlicí, 56218 Ústí nad Orlicí, Czech Republic
700    1_
$a Marek, Jan $u Long-Term Care Facility Albertinum Žamberk, 56401 Žamberk, Czech Republic
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 15, č. 9 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37765236 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093518 $b ABA008
999    __
$a ok $b bmc $g 1997093 $s 1201685
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 9 $e 20230901 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a NA $p Contipro (Czechia)
LZP    __
$a Pubmed-20231010

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...